140 related articles for article (PubMed ID: 36385665)
41. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
42. CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.
Grabauskiene S; Bergeron EJ; Chen G; Chang AC; Lin J; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
Lung Cancer; 2013 Dec; 82(3):477-84. PubMed ID: 24113549
[TBL] [Abstract][Full Text] [Related]
43. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
44. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.
Vaughan CA; Pearsall I; Singh S; Windle B; Deb SP; Grossman SR; Yeudall WA; Deb S
Oncotarget; 2016 Mar; 7(11):12426-46. PubMed ID: 26820293
[TBL] [Abstract][Full Text] [Related]
45. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
Zhang EB; Yin DD; Sun M; Kong R; Liu XH; You LH; Han L; Xia R; Wang KM; Yang JS; De W; Shu YQ; Wang ZX
Cell Death Dis; 2014 May; 5(5):e1243. PubMed ID: 24853421
[TBL] [Abstract][Full Text] [Related]
46. YAP mediates the positive regulation of hnRNPK on the lung adenocarcinoma H1299 cell growth.
Xu L; Zhang T; Huang W; Liu X; Lu J; Gao X; Zhang YF; Liu L
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):677-687. PubMed ID: 31187136
[TBL] [Abstract][Full Text] [Related]
47. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
Xu CX; Zhao L; Yue P; Fang G; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Cancer Biol Ther; 2011 Sep; 12(6):549-55. PubMed ID: 21738008
[TBL] [Abstract][Full Text] [Related]
48. Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells.
Pan ST; Zhou J; Yang F; Zhou SF; Ren T
BMC Cancer; 2020 Jul; 20(1):634. PubMed ID: 32641008
[TBL] [Abstract][Full Text] [Related]
49. Yes-associated protein regulates the growth of human non-small cell lung cancer in response to matrix stiffness.
Yuan Y; Zhong W; Ma G; Zhang B; Tian H
Mol Med Rep; 2015 Jun; 11(6):4267-72. PubMed ID: 25607725
[TBL] [Abstract][Full Text] [Related]
50. C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer.
Li H; Liu J; Cao W; Xiao X; Liang L; Liu-Smith F; Wang W; Liu H; Zhou P; Ouyang R; Yuan Z; Liu J; Ye M; Zhang B
Theranostics; 2019; 9(18):5134-5148. PubMed ID: 31410206
[No Abstract] [Full Text] [Related]
51. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
Oncotarget; 2014 Jul; 5(13):4765-78. PubMed ID: 24946858
[TBL] [Abstract][Full Text] [Related]
52. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.
Lo Sardo F; Forcato M; Sacconi A; Capaci V; Zanconato F; Di Agostino S; Del Sal G; Pandolfi PP; Strano S; Bicciato S; Blandino G
Carcinogenesis; 2017 Jan; 38(1):64-75. PubMed ID: 27797825
[TBL] [Abstract][Full Text] [Related]
53. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
54. m
Jin D; Guo J; Wu Y; Yang L; Wang X; Du J; Dai J; Chen W; Gong K; Miao S; Li X; Sun H
Mol Cancer; 2020 Feb; 19(1):40. PubMed ID: 32106857
[TBL] [Abstract][Full Text] [Related]
55. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway.
Niu R; Li D; Chen J; Zhao W
Cell Cycle; 2022 Jan; 21(1):86-100. PubMed ID: 34919024
[TBL] [Abstract][Full Text] [Related]
56. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
57. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.
Sankala H; Vaughan C; Wang J; Deb S; Graves PR
Arch Biochem Biophys; 2011 Aug; 512(1):52-60. PubMed ID: 21621504
[TBL] [Abstract][Full Text] [Related]
58. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
59. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
60. The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation.
Wang W; Huang Q; Chen Y; Huang Z; Huang Y; Wang Y; Qi X; Liu Z; Lu L
Pharmacol Res; 2021 Aug; 170():105723. PubMed ID: 34116210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
